All In Biotech

Drug Trial Radar · NCT04707248

A Study of DS-6000a in Subjects With Advanced Renal Cell Carcinoma and Ovarian Tumors

Phase I, Two-Part, Multi-Center, First-in-Human Study of DS-6000a in Subjects With Advanced Renal Cell Carcinoma and Ovarian Tumors

Last checked: Nov 19, 2026Latest source record: Sep 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

179

Actual

Start

Dec 22, 2020

Primary completion

Dec 30, 2026

Study completion Dec 30, 2026

Sponsor

Lead sponsor
Daiichi SankyoDaiichi Sankyo (DSNKY)
Sponsor type
Industry
Collaborators
Merck Sharp & Dohme LLC
First posted
Jan 13, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This clinical trial will evaluate raludotatug deruxtecan (R-DXd; DS-6000a) in participants with advanced renal cell carcinoma (RCC) and ovarian cancer (OVC). The main goals of this study will be to investigate the recommended dose of R-DXd that can be given safely to participants, assess the adverse events of R-DXd, and evaluate the effectiveness of R-DXd.

Conditions

  • Renal Cell Carcinoma
  • Ovarian Tumor

Interventions

  • DS-6000aDrug

    Intravenous administration at doses starting at 1.6 mg/kg on Day 1 of Cycle 1

  • DS-6000aDrug

    Intravenous administration at RDE on Day 1 of Cycle 1

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Dose-limiting toxicities (DLTs)Time frame: Day 1 to Day 21 in Cycle 1 (each cycle is 21 days)
  2. Number of Participants Reporting Treatment-emergent Adverse Events, Serious Adverse Events, and Adverse Events of Special InterestTime frame: From start of treatment up to 40 days after last dose, up to approximately 52 months
  3. Objective Response Rate (ORR) Based on Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) (Dose Expansion)Time frame: From start of treatment (Cycle 1, Day 1) up to disease progression, up to approximately 52 months (each cycle is 21 days)

Locations

13 sites in 2 countries. Site status is shown where the registry gives one.

  • Arizona Oncology Associates, PC HOPE (A)A HOPE)

    Tucson, Arizona

  • Rocky Mountain Cancer Center

    Denver, Colorado

  • Florida Cancer Lake Mary

    Lake Mary, Florida

  • Oklahoma University

    Oklahoma City, Oklahoma

  • SCRI Oncology Partners

    Nashville, Tennessee

  • Vanderbilt-Ingram Cancer Center

    Nashville, Tennessee

  • National Hospital Organization Kyusyu Cancer Center

    Fukuoka, Japan

  • The Cancer Institute Hospital of Japanese Foundation for Cancer Research

    Kōtoku, Japan

  • National Hospital Organization Shikoku Cancer Center

    Matsuyama, Japan

  • Shizuoka Cancer Center

    Nakatogari, Japan

  • Saitama Medical University International Medical Center

    Saitama, Japan

  • National Cancer Center Hospital

    Chuo Ku, Tokyo, Japan

  • National Cancer Center Hospital East

    Kashiwa-shi, Tokyo, Japan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.